Rotavirus Infections clinical trials
The registry lists 104 studies for Rotavirus Infections across more than 10 countries. 3 are recruiting or about to start. 96 of them are mainly about Rotavirus Infections (how this is decided). Per ClinicalTrials.gov, last updated 2026-05-26.
Get an email when these change. Save the Rotavirus Infections studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
GlaxoSmithKline (61) · Merck Sharp & Dohme LLC (9) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (2) · Romark Laboratories L.C. (2) · Limited Liability Company Pharm Aid (2) · Centro Pediatrico Albina de Patino (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Centers for Disease Control and Prevention (2)
What is being tested here
Drugs under test in Rotavirus Infections studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Who these studies take
Of the 3 Rotavirus Infections studies recruiting now, 0 (0%) set no upper age limit and 3 (100%) stop at 75 or younger. 3 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (100%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (33%) | 1 (33%) |
| 18 | 1 (33%) | 1 (33%) |
| 30 | 1 (33%) | 1 (33%) |
| 40 | 1 (33%) | 1 (33%) |
| 50 | 1 (33%) | 1 (33%) |
| 65 | 1 (33%) | 1 (33%) |
| 75 | 1 (33%) | 1 (33%) |
| 85 | 0 (0%) | 0 (0%) |
Across all 104 studies, recruiting or not: 95% stop at 75 or younger and 94% at 65; 93% take children; 1% are for women only and 2% for men only; 75% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Rotavirus Infections studies take
Of 14 phase 3 interventional studies under Rotavirus Infections, half reached primary completion within 12 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 3 | 12 mo7–20 · 14 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
Studies
Recruiting first, then most recently updated. Showing 50 of 104. Browse all 104 → or search them.
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveRecruitingNCT073589101 country
- Phase II Clinical Trial of the Inactivated Rotavirus VaccineRecruitingNCT06080906Phase 21 country
- A Trial to Assess the Safety, Immunogenicity and Efficacy of a Trivalent Rotavirus P2-VP8 Subunit Vaccine in Prevention of Severe Rotavirus Gastroenteritis in Healthy Infants in Africa and IndiaRecruitingNCT04010448Phase 31 country
- CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy AdultsCompletedNCT06485258Phase 11 country
- CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy AdultsActive, not recruitingNCT06962904Phase 11 country
- SaniVac Trial - Sanitation and Oral Rotavirus Vaccine PerformanceCompletedNCT033131281 country
- The Efficacy of Oral Rotavirus Vaccine 116E (ROTAVAC 5D) in Chilean InfantsActive, not recruitingNCT06200844Phase 31 country
- Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and ToddlersActive, not recruitingNCT05621655Phase 21 country
- A Phase II Dose-ranging Study of Oral RV3-BB Rotavirus VaccineCompletedNCT03483116Phase 21 country
- A Surveillance Study on Timing and Coverage Of Rotavirus and MenB Vaccine Co-administration in Campania Region, ItalyStatus unknownNCT05212935
- Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 WeeksCompletedNCT03954743Phase 35 countries
- Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children Born to HIV-infected MothersCompletedNCT00880698Phase 24 countries
- Safety and Immunological Efficacy of the Pentavalent Rotavirus Vaccine - Rota-V-Aid™ (Live Attenuated Oral, Freeze-dried) at Healthy Adults Aged 18 to 45 Years.CompletedNCT05037435Phase 31 country
- Reactogenicity, Safety and Immunological Efficacy of the Live, Pentavalent Rotavirus Vaccine in Childhood ImmunizationCompletedNCT05032391Phase 31 country
- To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First VaccinationCompletedNCT003533661 country
- This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized VaccineCompletedNCT03207750Phase 31 country
- Safety and Preliminary Immunogenicity Study of Inactivated Vaccine for Prevention of Rotavirus InfectionStatus unknownNCT04626856Phase 11 country
- A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South AfricaCompletedNCT00263666Phase 21 country
- The Effects of Increased Inoculum on Oral Rotavirus Vaccine Take and ImmunogenicityCompletedNCT02992197Phase 41 country
- Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 WeeksCompletedNCT02914184Phase 38 countries
- Evaluation of an Infant Immunization Encouragement Program in NigeriaCompletedNCT03870061Not applicable1 country
- Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix (Human Rotavirus Vaccine) in InfantsCompletedNCT007508931 country
- Study to Evaluate Immunogenicity, Reactogenicity and Safety of Rotarix™ Vaccine in Korean InfantsCompletedNCT00969228Phase 41 country
- Effectiveness Study of GSK Biologicals' Rotarix TM Vaccine in Hospitalized ChildrenCompletedNCT011778261 country
- Efficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese InfantsCompletedNCT00480324Phase 31 country
- A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants.CompletedNCT00432380Phase 21 country
- A Study to Test 2 Doses of the HRV Vaccine in Healthy Infants.CompletedNCT00140673Phase 312 countries
- Evaluate Protective Efficacy of Diff Strengths of Human Rotavirus Vaccine After Admn of 2 Doses to Infants Aged 2 MonthsCompletedNCT00385320Phase 2
- Study to Assess the Impact of Vaccination on Hospitalizations and Outpatient Visits Due to Rotavirus GastroenteritisCompletedNCT017338621 country
- Evaluate Immunogenicity, Safety, and Reactogenicity of Rotavac® in Healthy Infants Aged Between 6-8 Weeks in VietnamStatus unknownNCT03367559Phase 31 country
- A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus VaccineCompletedNCT01764256Phase 11 country
- Safety Study of GSK Biologicals' Rotavirus Vaccine (Rotarix®) Administered to Children Aged <1 Year in the United StatesCompletedNCT008756411 country
- Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060)CompletedNCT01926015Phase 4
- Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix™ (Human Rotavirus Vaccine) in InfantsCompletedNCT007797791 country
- Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine.CompletedNCT00420316Phase 31 country
- Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.CompletedNCT01198769Phase 41 country
- Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese InfantsCompletedNCT01171963Phase 31 country
- Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot StudyCompletedNCT02542462Phase 41 country
- RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)CompletedNCT00443846Phase 3
- To Assess Immunogenicity, Reactogenicity & Safety of 2 Formulations of GSK's HRV Vaccine as 2-dose Vaccination (Infants)CompletedNCT00363545Phase 31 country
- To Assess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK's Oral Human Rotavirus Vaccine in Pre-Term InfantsCompletedNCT00420745Phase 34 countries
- Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of AgeCompletedNCT00533507Phase 31 country
- Number of Rotavirus (RV) Related Hospitalizations in Belgium - Season 2010-2011CompletedNCT01563159
- Number of Rotavirus (RV) Related Hospitalizations in Belgium - Season 2006-2007CompletedNCT01563146
- A Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vaccine Strain Between Twins Within a Family.CompletedNCT00396630Phase 31 country
- Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Indian InfantsCompletedNCT009383271 country
- Effectiveness of Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) in Infants in PanamaCompletedNCT006531981 country
- The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune ResponsesCompletedNCT02538211Not applicable1 country
- Assess the Immunogenicity & Safety of 2 Doses of Oral Live Attenuated Human Rota(HRV)Vaccine in Healthy Infants in IndiaCompletedNCT00289172Phase 31 country
- Study to Assess the Safety of GSK Biologicals' Liquid Human Rotavirus Vaccine in Healthy InfantsCompletedNCT01107587Phase 11 country